Company intelligence / Profile preview

Arrys Therapeutics, Inc.

Cambridge, Massachusetts, United Statesdnb.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Arrys Therapeutics completed a Phase I trial (NCT03658772) for grapiprant in metastatic colorectal cancer. The trial assessed safety and tolerability of grapiprant in combination with Merck's Keytruda (pembrolizumab) and enrolled 54 patients. The drug's Probability of Technical Success Rating (PTSR) increased by 11 points to 75% following trial completion.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

ARY-007

Phase 1

Indications: Cancer

Partnerships

AskAt Inc.

Beyond the preview

Go deeper on Arrys Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrys Therapeutics, Inc..

Explore the full profile